BioElectronics Corporation Announces South Korean Patent Allowance for its Innovative OTC Pain Relief Medical Devices
Published: Jan 22, 2013
FREDERICK, Md., Jan. 22, 2013 /PRNewswire/ -- BioElectronics Corporation (OTCPK: BIEL), maker of consumer medical electronics, announced today that the Company has received patent allowance from the South Korean Intellectual Property office.
While pulsed shortwave therapy is an established medical therapy, this South Korean patent and our 9 other approved and 8 pending are for a self contained medical device that is affixed to the body with a flexible antenna that allows the patient to move more freely. A visual monitor confirms that the antenna transmits energy at less than 1 milli-watt to provide extended duration home therapy. This low power extended duration therapy is 5x's better than OTC drugs, 100% safer and costs less than $0.25 for overnight pain relief.
"We appreciate the importance of protecting our intellectual property throughout the world," said John Martinez, Director of Engineering at BioElectronics. "This patent and our portfolio of patents provide confirmation of our sound science and are valuable assets in our accumulated body of knowledge."
About BioElectronics Corporation
BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay Menstrual Cycle Pain Therapy, and RecoveryRx for surgical procedures and wound care.
SOURCE BioElectronics Corporation